Compare FXNC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | PRQR |
|---|---|---|
| Founded | 1907 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.6M | 250.7M |
| IPO Year | N/A | 2014 |
| Metric | FXNC | PRQR |
|---|---|---|
| Price | $24.51 | $2.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.14 |
| AVG Volume (30 Days) | 15.7K | ★ 348.1K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 10.94 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $81,206,000.00 | $18,859,556.00 |
| Revenue This Year | $57.18 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $19.70 | ★ N/A |
| Revenue Growth | ★ 66.40 | N/A |
| 52 Week Low | $18.26 | $1.07 |
| 52 Week High | $26.97 | $3.97 |
| Indicator | FXNC | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 53.26 |
| Support Level | $23.07 | $2.10 |
| Resistance Level | $24.45 | $2.40 |
| Average True Range (ATR) | 0.67 | 0.17 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 83.80 | 89.49 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. Key revenue is generated from Community Banking.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.